ADC Therapeutics Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Revenues: $18.6 million for Q2 2026, up from $18.1 million in Q2 2025.

Cost of Product Sales: $2.3 million for Q2 2026, compared to $0.8 million in Q2 2025.

Total Operating Expenses: $44.7 million for Q2 2026; adjusted operating expenses (non-GAAP) were $37.2 million, a 22% decrease year-over-year.

Net Loss: $16.6 million for Q2 2026, significantly improved from a net loss of $56.6 million in Q2 2025. Non-GAAP adjusted net loss was $16.3 million, down from $28.7 million in the prior year.

Cash Position: $219.1 million at the end of Q2 2026, providing a cash runway into 2028.

2Strategic Updates and Business Highlights

ZYNLONTA Performance: Continued strong performance in the third-line plus DLBCL market, with approximately 5,000 patients treated since FDA accelerated approval in 2021.

Pipeline Progress:

LOTIS-5: Phase III trial met primary endpoint of progression-free survival; however, FDA raised concerns about benefit-risk assessment. ADC Therapeutics is evaluating regulatory pathways.

LOTIS-7: Completed enrollment of 100 patients for the combination of ZYNLONTA and glofitamab, with promising data expected to position it as a leading second-line treatment in DLBCL. Plans to submit for breakthrough designation this year.

Cost-Saving Measures: A strategic reorganization led to a 17% workforce reduction, expected to save approximately $10 million annually.

3Forward Guidance and Outlook

ADC Therapeutics anticipates growth in ZYNLONTA's market presence starting in 2027, with ongoing efforts to expand its use into earlier lines of therapy and indolent lymphomas.

The company is preparing for data presentations at ASH and expects to submit for publication and compendia inclusion for LOTIS-5 and LOTIS-7.

4Challenges and Points of Concern

Regulatory Risks: The FDA's concerns regarding the LOTIS-5 trial could impact the regulatory path for ZYNLONTA, although the company remains confident in the monotherapy's continued market presence.

Safety Concerns: The LOTIS-5 trial reported Grade 5 infections, primarily bacterial, raising questions about safety and potential implications for future studies and compendia inclusion.

Market Competition: The evolving competitive landscape in DLBCL may pose challenges as ADC Therapeutics seeks to solidify ZYNLONTA’s position.

5Notable Q&A Insights

FDA Discussions: There were no concerns raised about ZYNLONTA's accelerated approval status as a monotherapy, despite the issues with the combination therapy in LOTIS-5.

LOTIS-7 Data: The company expressed confidence in the compelling efficacy and safety data from LOTIS-7, which has been submitted for ASH presentation.

Phase III Exploration: ADC Therapeutics is considering a Phase III trial for the ZYNLONTA and glofitamab combination, with ongoing discussions with Roche and plans for breakthrough designation.

Patient Safety Protocols: Differences in safety protocols between LOTIS-5 and LOTIS-7 were emphasized, particularly the inclusion of prophylactic measures in LOTIS-7 that could mitigate risks observed in LOTIS-5. This summary encapsulates the key financial metrics, strategic initiatives, forward-looking statements, and challenges faced by ADC Therapeutics as discussed in their Q2 2026 earnings call.